Financial Position - Zura Bio reported cash and cash equivalents of 176.5millionasofDecember31,2024,upfrom99.8 million as of December 31, 2023, indicating a significant increase of 76.8%[9]. - Zura Bio's total assets increased to 179.5millionasofDecember31,2024,comparedto100.8 million in 2023, indicating strong growth in the company's financial position[18]. - Zura Bio completed a 112.5millionprivateplacementfinancinginApril2024,contributingtoatotalcashpositionthatsupportsoperationsthrough2027[6].Expenses−Researchanddevelopmentexpensesdecreasedto24.4 million for the year ended December 31, 2024, down 44.5% from 44.0millionin2023,primarilyduetoaone−timeacquisitioncostinthepreviousyear[10].−Generalandadministrativeexpensesroseto30.8 million in 2024, an increase of 65.5% compared to 18.6millionin2023,drivenbyhighercompensationandprofessionalfees[11].−Thetotaloperatingexpensesfor2024were55.2 million, a decrease from 62.6millionin2023,reflectingimprovedcostmanagement[20].NetLoss−ThenetlossfortheyearendedDecember31,2024,was45.4 million, or 0.60pershare,areductionfromanetlossof69.2 million, or $2.09 per share, in 2023[12]. Clinical Development - Zura Bio initiated the Phase 2 TibuSURE trial for systemic sclerosis (SSc) in December 2024, marking a key milestone in its clinical pipeline[4]. - The company plans to launch a Phase 2 trial for hidradenitis suppurativa (HS) in Q2 2025, further expanding its clinical research efforts[7]. - The company established a Scientific Advisory Board in June 2024, enhancing its clinical and scientific leadership capabilities[13].